This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
Last month, a court in Shanghai convicted a former employee of WuXi PharmaTech, a contract research organization with operations in the US and China, of stealing samples of two different Merck compounds that were being tested in Chinese facilities..........
The reports indicate that he stole small quantities of MK-3102, a GLP-1 inhibitor that is being developed to treat diabetes, and MK-5172, which is being devloped to combat hepatitis C, both of which were in Phase II testing as of last fall, according to the Merck pipeline (read here). After the thefts, Xiao offered them for sale on the Internet, which Merck later discovered. The thefts took place last year, although were apparently not disclosed until the recent sentencing.........
No comments:
Post a Comment